These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17319075)

  • 1. Release of antigen-specific immunoglobulin from cytotoxic effector cells and syngeneic tumour immunity in vitro.
    Röllinghoff M; Wagner H; Cone RE; Marchalonis JJ
    Nat New Biol; 1973 May; 243(122):21-3. PubMed ID: 17319075
    [No Abstract]   [Full Text] [Related]  

  • 2. Generation of cytotoxic lymphocytes by SV40-induced antigens.
    Chang C; Chang R; Mora PT; Hu CP
    J Immunol; 1982 May; 128(5):2160-3. PubMed ID: 6278025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cells must recognize tumor antigen in association with self-MHC antigen.
    Lannin DR; Yu S; McKhann CF
    Transplant Proc; 1981 Mar; 13(1 Pt 2):739-41. PubMed ID: 6168072
    [No Abstract]   [Full Text] [Related]  

  • 4. [New aspects of tumor immunology. Importance of the T-cell system].
    Knuth A; Dippold W; Meyer zum Büschenfelde KH
    Dtsch Med Wochenschr; 1982 Jul; 107(28):1105-10. PubMed ID: 6177489
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
    Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
    Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagen-induced antigenic variants of tumor cells.
    Boon T; Van Pel A; De Plaen E; Vessière F
    Symp Fundam Cancer Res; 1986; 38():139-48. PubMed ID: 3489258
    [No Abstract]   [Full Text] [Related]  

  • 8. Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
    Greenberg PD; Kern DE; Jensen MC; Klarnet JP; Cheever MA
    Prog Clin Biol Res; 1987; 244():127-35. PubMed ID: 2958868
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
    Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
    J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.
    Fujiwara H; Hamaoka T; Shearer GM; Yamamoto H; Terry WD
    J Immunol; 1980 Feb; 124(2):863-9. PubMed ID: 6965392
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro induction of tumor specific immunity. VII. Does autosensitization occur with in vitro culture of T lymphocytes?
    Burton RC; Chism SE; Warner NL
    J Immunol; 1977 Oct; 119(4):1329-39. PubMed ID: 302281
    [No Abstract]   [Full Text] [Related]  

  • 12. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.
    Westwood JA; Murray WK; Trivett M; Haynes NM; Solomon B; Mileshkin L; Ball D; Michael M; Burman A; Mayura-Guru P; Trapani JA; Peinert S; Hönemann D; Miles Prince H; Scott AM; Smyth MJ; Darcy PK; Kershaw MH
    J Immunother; 2009 Apr; 32(3):292-301. PubMed ID: 19242371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunology of tumors].
    Clerici E
    Minerva Nefrol; 1983; 30(2 Suppl):13-8. PubMed ID: 6866320
    [No Abstract]   [Full Text] [Related]  

  • 14. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells.
    Liu S; Lizée G; Lou Y; Liu C; Overwijk WW; Wang G; Hwu P
    Int Immunol; 2007 Oct; 19(10):1213-21. PubMed ID: 17898044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissection of tumour-specific antigenicity.
    Wortzel RD; Stauss HJ; Van Waes C; Schreiber H
    Cancer Surv; 1985; 4(1):115-34. PubMed ID: 3879854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine polyomavirus tumour specific transplantation antigens and viral persistence in relation to the immune response, and tumour development.
    Ramqvist T; Dalianis T
    Semin Cancer Biol; 2009 Aug; 19(4):236-43. PubMed ID: 19505651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
    Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
    Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.
    Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C
    J Clin Invest; 2007 Oct; 117(10):3087-96. PubMed ID: 17885685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice.
    Baschuk N; Utermöhlen O; Gugel R; Warnecke G; Karow U; Paulsen D; Brombacher F; Krönke M; Deppert W
    Cancer Immunol Immunother; 2007 Oct; 56(10):1625-36. PubMed ID: 17431618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.